Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation

Circulation Research

Volumn 106, Issue 11, 2010, Pages 1675-1680

  Leask, Andrew ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Endothelin; Fibrosis; PDGF; Scarring; TGF

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN RECEPTOR ANTAGONIST; HEPARAN SULFATE; IMATINIB; LOSARTAN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DNA BINDING; DOWNSTREAM PROCESSING; EPITHELIZATION; EXTRACELLULAR MATRIX; FIBROBLAST; GRANULATION TISSUE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REPAIR; WOUND; WOUND HEALING;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR AGENTS; CONNECTIVE TISSUE GROWTH FACTOR; DRUG DESIGN; ENDOTHELIN-1; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBROSIS; HEART DISEASES; HUMANS; MYOCARDIUM; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953808712     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.217737     Document Type: Review

References (70)

1. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500-503.
2. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807-1816.
3. Leask A. Targeting the TGF/3, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 2008;20:1409-1414.
4. Kane CJ, Hebda PA, Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. Cell Physiol. 1991;148: 157-173.
5. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67: 753-791.
6. Leask A, Abraham DJ. TG F-beta signaling and the fibrotic response. FASEB J. 2004;18:816-827.
7. Roberts AB. TG F-beta signaling from receptors to the nucleus. Microbes Infect. 1999;1:1265-1273.
8. Santander C, Brandan E. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell Signal. 2006;18:1482-1491.
9. Liu S, Shi-wen X, Kennedy L, Pala D, Carter DE, Black CM, Abraham DJ, Leask A. FAK is required for TGF/3-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix remodeling pheno-type. Mol Biol Cell. 2007;18:2169-2178.
10. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM, Thomas PE. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003;278:12384-12389.
11. Shi-wen X, Parapuram SK, Pala D, Chen Y, Carter D, Eastwood M, Abraham DJ, Leask A. TGF/3-induced a-smooth muscle actin expression and extracellular matrix contraction in fibroblasts requires TAK1. Arthritis Rheum. 2009;60:234-241.
12. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987;237:1333-1336.
13. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107:1137-1157.
14. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS, Khaw PT. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003;10:59-71.
15. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol. 1999;1:260-266.
16. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol. 2002;160:1057-1068.
17. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Bottinger EP. Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci USA. 2003;100:10269- 10274.
18. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001;276:17058-17062.
19. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF, Frangogiannis NG. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007;116:2127-2138.
20. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003;278:13008-13015.
21. Xie S, Sukkar MB, Issa R, Oltmanns U, Nicholson AG, Chung KF. Regulation of TGF-beta 1-induced connective tissue growth factor expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:L68-L76.
22. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol. 2006;70:1992-2003.
23. Jadrich JL, O'Connor MB, Coucouvanis E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development. 2006;133:1529-1541.
24. Shi-wen X, Rodrigues-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A. Constitutive ALK5-indepenent JNK activation contributes to endothelin-1 over-expression in pulmonary fibrosis. Mol Cell Biol. 2006; 26:5518-5527.
25. Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 2006;54:1309-1316.
26. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
27. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103:485-492.
28. Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 (ALK5) signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol. In press.
29. Holtz J. Pathophysiology of heart failure and the renin-angiotensin- system. Basic Res Cardiol. 1993;88(Suppl 1):183-201.
30. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
31. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardio-myocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796.
32. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension. 2009;54:877-884.
33. Gao X, He X, Luo B, Peng L, Lin J, Zuo Z. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol. 2009;606:115-120.
34. Martin MM, Buckenberger JA, Jiang J, Malana GE, Knoell DL, Feldman DS, Elton TS. TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2007; 293:L790-L799.
35. Rodríguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-/3-independent mechanism. Circulation. 2005;111:2509-2517.
36. De Mello WC, Specht P. Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. J Renin Angiotensin Aldosterone Syst. 2006;7:201-205.
37. Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y, Nishikawa M, Matsubara H, Iwasaka T. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res. 2005;28:787-795.
38. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med. 2005;37:2-12.
39. Teder P, Noble PM. A cytokine reborn: endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol. 2000;23:7-10.
40. Shi-wen X, Kennedy L, Renzoni E, du Bois R, Denton C, Black C, Abraham D, Leask A. Endothelin-1 is a downstream mediator of TGF/3 in fibroblasts. Arthritis Rheum. 2007;56:4189-4194.
41. Shephard P, Hinz B, Smola-Hess S, Meister JJ, KriegT, SmolaH. Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb Haemost. 2004;92:262-274.
42. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol. 2003;42:1845-1854.
43. Mucke HA. Pulmonary arterial hypertension: on the way to a manageable disease. Curr Opin Investig Drugs. 2008;9:957-962.
44. Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, Gu Z, Kane B, Fadnis L, Baska RA, Beyer S, Arthur S, Dickinson K, Zhang D, Perrone M, Ferrer P, Giancarli M, Baumann J, Bird E, Panchal B, Yang Y, Trippodo N, Barrish J, Macor JE. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. J Pharmacol Exp Ther. 2004;309:275-284.
45. Palaniswamy C, Selvaraj DR, Palaniappan D. Dual angiotensin II and endothelin receptor antagonists. Am J Ther. In press.
46. Leask A, Abraham DJ. All in the CCN family. J Cell Sci. 2006;119: 4803-4810.
47. Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C, Stratton R. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM. 2005;98:485-492.
48. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf). 2009;195:321-338.
49. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol. 1999;181:153-159.
50. Bonniaud P, Martin G, Margetts PJ, Ask K, Robertson J, Gauldie J, Kolb M. Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs. Am J Respir Cell Mol Biol. 2004;31:510-516.
51. Shi-wen X, Stanton L, Kennedy L, Pala D, Chen Y, Howat SL, Renzoni EA, Carter DE, Bou-Gharios G, Stratton RJ, Pearson JD, Beier F, Lyons KM, Black CM, Abraham DJ, Leask A. CCN2 is necessary for adhesive responses to TGF/31 in embryonic fibroblasts. J Biol Chem. 2006;281:10715-10726.
52. Kennedy L, Liu S, Shi-wen X, Carter D, Lyons K, Black CM, Abraham DJ, Leask A. CCN2 is essential for fibroblast function. Exp Cell Res. 2007;313:952-964.
53. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun. 2008;370:274-278.
54. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E, Perrot A, Geier C, Dietz R, Morano I, Bader M, Ozcelik C. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One. 2009;4:e6743.
55. Brigstock DR. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): from pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J Cell Commun Signal. 2009;3:5-18.
56. Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60:2142-2155.
57. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255-273.
58. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000;8:13-25.
59. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
60. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood. 2004;104:3198-3204.
61. Rhee S, Grinnell F. P21-activated kinase 1: convergence point in PDGF-and LPA-stimulated collagen matrix contraction by human fibroblasts. J Cell Biol. 2006;172:423-432.
62. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C, a novel growth factor, in human dermal fibroblasts. J Cell Physiol. 2005;202:510-517.
63. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 1999;42:930-941.
64. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, Gerdin B, Denton CP, Bou-Gharios G, Black CM, Abraham DJ. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol. 2006;169:2254-2265.
65. Kapoor M, Liu S, Huh K, Parapuram S, Kennedy L, Leask A. Connective tissue growth factor promoter activity in normal and wounded skin. Fibrogenesis Tissue Repair. 2008;1:3.
66. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214-2222.
67. Tuuminen R, Nykanen AI, Krebs R, Soronen J, Pajusola K, Keranen MA, Koskinen PK, Alitalo K, Lemstrom KB. PDGF-A,-C, and-D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts. Arterioscler Thromb Vasc Biol. 2009:29:691-698.
68. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P, Nakauchi H, Nakaya H, Komuro I. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120:242-253.
69. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res. 2008;102:319-327.
70. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, Talor MV, Baldeviano GC, Frisancho S, Gabrielson K, Bedja D, Rose NR. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172:1195-1208.